

Curriculum Vitae

Personal Data

Title	Prof. Dr. med.
First name	Robert
Name	Zeiser
Current position	Full Professor (W3)
Current institution(s)/site(s), country	Department of Hematology and Oncology, Medical Center – University of Freiburg, Freiburg, Germany
Identifiers/ORCID	ORCID-ID: 0000-0001-6565-3393

Qualifications and Career

Stages	Periods and Details
Degree programme	1995-2001, Medical Study at University of Freiburg, Freiburg, Germany
Doctorate	2001, Prof. Dr. Schaefer, Dissertation in Medicine, University of Freiburg, Freiburg, Germany
Stages of academic/professional career	2023: Deputy Director of the Dept. Internal Medicine I Director of the Division of Stem Cell Transplantation 2019: Director of the Division of Tumor Immunology 2016: W3 Full Professorship 2013: Heisenberg Professorship 2010: Consultant physician, Dept. of Hematology and Oncology, Freiburg 2007-2010: Assistant Physician, Dept. of Hematology and Oncology, Freiburg 2005-2007: Postdoctorate, Stanford University School of Medicine (Lab of Dr Negrin), BMT Department, USA 2001-2004: Internship in Internal Medicine, Dept. of Hematology and Oncology, Freiburg

Activities in the Research System

Committees and faculty responsibilities:

2021 - ongoing	SFB 1479 "OncoEscape": Speaker
2019 - ongoing	SFB/TRR 167: PI and Member in the SFB Board
2018 - ongoing	SFB 1160: PI and Member in the SFB Board
2023 - ongoing	German Cancer Aid: Grants committee (Fachausschuss Nachwuchsförd.)
2024 - ongoing	José Carreras Leukämie-Stiftung: Grants committee
2014 - 2023	SFB 850: PI and Vice-Speaker
2009 - 2013	SFB 620: PI

Editorial Boards:

Since 2016 Associate Editor of the Journal *Blood*; American Society of Hematology

Reviewer activities:

Cell, Science, Nature Medicine, Nature Immunology, Nature Reviews Cancer, New England Journal of Medicine, Lancet Haematology, Blood, JCI

Mentoring: Mentor at six mentoring programs (SGBM, SUCCESS, IMBS, IRTG, B. Ottenstein Program, IMMEDIATE Advanced Clinician Scientist (ACS) - Program), Several former AG Zeiser students have leadership positions in academia including two full professorships.

Organisation of scientific meetings: Annual Meeting of the American Society of Hematology educational session in 2018-2023, For 2024: Educational session on Immunology and Host

defence. European Hematology association (EHA), educational sessions on stem cell transplantation 2022, 2023 and 2024.

Scientific Results

Category A

1. Braun LM, Giesler S, Andrieux G, Riemer R, Talvard-Balland N, Duquesne S, Rückert T, Unger S, Kreutnair S, Zwick M, Follo M, Hartmann A, Osswald N, Melchinger W, Chapman S, Hutchinson JA, Haferkamp S, Torster L, Kött J, Gebhardt C, Hellwig D, Karantzelis N, Wallrabenstein T, Lowinus T, Yücel M, Brehm N, Rawluk J, Pfeifer D, Bronsert P, Rogg M, Mattern S, Heikenwälder M, Fusco S, Malek NP, Singer S, Schmitt-Graeff A, Ceteci F, Greten FR, Blazar BR, Boerries M, Köhler N, Duyster J, Ihorst G, Lassmann S, Keye P, Minguet S, Schadendorf D, Ugurel S, Rafei-Shamsabadi D, Thimme R, Hasselblatt P, Bengsch B, Schell C, Pearce EL, Meiss F, Becher B, Funke-Lorenz C, Placke JM, Apostolova P, **Zeiser R**. Adiponectin reduces immune checkpoint inhibitor-induced inflammation without blocking anti-tumor immunity. *Cancer Cell*. 2025 Feb 10;43(2):269-291.e19. doi: 10.1016/j.ccell.2025.01.004.
2. Vinnakota JM, Biavasco F, Schwabenland M, Chhatbar C, Adams RC, Erny D, Duquesne S, El Khawanky N, Schmidt D, Fetsch V, Zähringer A, Salié H, Athanassopoulos D, Braun LM, Javorniczky NR, Ho JNHG, Kierdorf K, Marks R, Wäsch R, Simonetta F, Andrieux G, Pfeifer D, Monaco G, Capitini C, Fry TJ, Blank T, Blazar BR, Wagner E, Theobald M, Sommer C, Stelljes M, Reicherts C, Jeibmann A, Schittenhelm J, Monoranu CM, Rosenwald A, Kortüm M, Rasche L, Einsele H, Meyer PT, Brumberg J, Völkl S, Mackensen A, Coras R, von Bergwelt-Baildon M, Albert NL, Bartos LM, Brendel M, Holzgreve A, Mack M, Boerries M, Mackall CL, Duyster J, Henneke P, Priller J, Köhler N, Strübing F, Bengsch B, Ruella M, Subklewe M, von Baumgarten L, Gill S, Prinz M, **Zeiser R**. Targeting TGF β -activated kinase-1 activation in microglia reduces CAR T immune effector cell-associated neurotoxicity syndrome. *Nature Cancer*. 2024 Aug;5(8):1227-1249, doi: 10.1038/s43018-024-00764-7.
3. Vinnakota JM, Adams RC, Athanassopoulos D, Schmidt D, Biavasco F, Zähringer A, Erny D, Schwabenland M, Langenbach M, Wenger V, Salié H, Cook J, Mossad O, Andrieux G, Dersch R, Rauer S, Duquesne S, Monaco G, Wolf P, Blank T, Häne P, Greter M, Becher B, Henneke P, Pfeifer D, Blazar BR, Duyster J, Boerries M, Köhler N, Chhatbar CM, Bengsch B, Prinz M, **Zeiser R**. Anti-PD-1 cancer immunotherapy induces central nervous system immune-related adverse events by microglia activation. *Science Translational Medicine* 2024; 16(751): eadj9672. doi: 10.1126/scitranslmed.adj9672.
4. Ho JNHG, Schmidt D, Lowinus T, Ryoo J, Dopfer EP, Gonzalo Núñez N, Costa-Pereira S, Toffalori C, Punta M, Fetsch V, Wertheimer T, Rittmann MC, Braun LM, Follo M, Briere C, Vinnakota JM, Langenbach M, Koppers F, Shoumariyeh K, Engel H, Rückert T, Märklin M, Holzmayer S, Illert AL, Magon F, Andrieux G, Duquesne S, Pfeifer D, Staniek J, Rizzi M, Miething C, Köhler N, Duyster J, Menssen HD, Boerries M, Buescher JM, Cabezas-Wallscheid N, Blazar BR, Apostolova P, Vago L, Pearce EL, Becher B, **Zeiser R**. Targeting MDM2 enhances antileukemia immunity after allogeneic transplantation via MHC-II and TRAIL-R1/2 upregulation. *Blood*. 2022 Sep 8;140(10):1167-1181. doi: 10.1182/blood.2022016082
5. **Zeiser, R.**, Polverelli N, Ram R, Hashmi SK, Chakraverty R, Middeke JM, Musso M, Giebel S, Uzay A, Langmuir P, Hollaender N, Gowda M, Stefanelli T, Lee SJ, Teshima T, Locatelli F; REACH3 Investigators. (2021). Ruxolitinib for Glucocorticoid-Refractory Chronic Graft-versus-Host Disease. *New England Journal of Medicine* 385(3), 228-238; doi:10.1056/NEJMoa2033122
6. **Zeiser, R.**, von Bubnoff N, Butler J, Mohty M, Niederwieser D, Or R, Szer J, Wagner EM, Zuckerman T, Mahuzier B, Xu J, Wilke C, Gandhi KK, Socié G, for the REACH2 Trial Group. (2020). Ruxolitinib for Glucocorticoid-Refractory Acute Graft-versus-Host Disease. *New England Journal of Medicine* 382(19), 1800-1810; doi:10.1056/NEJMoa1917635
7. Uhl F, Chen S, O'Sullivan D, Edwards-Hicks J, Richter G, Haring E, Andrieux G, Halbach S, Apostolova P, Büscher J, Duquesne S, Melchinger W, Sauer B, Shoumariyeh K, Schmitt-Gräff A, Kreutz M, Lübbert M, Duyster J, Brummer T, Boerries M, Madl T, Blazar BR, Groß O, Pearce EL, **Zeiser R** (2020). Metabolic reprogramming of donor T cells enhances graft-versus-leukemia effects in mice and humans. *Science Translational Medicine* 12(567); doi:10.1126/scitranslmed.abb8969
8. Mathew NR, Baumgartner F, Braun L, David O'Sullivan, Thomas S, Waterhouse M, Müller TA, Hanke K, Taromi S, Apostolova P, Illert AL, Melchinger W, Duquesne S, Schmitt-Graeff A, Osswald L, Yan K-L., Weber A, Tugues S, Spath S, Pfeifer D, Follo M, Claus R, Lübbert M, Rummelt C, Bertz H, Wäsch R, Haag J, Schmidts A, Schultheiss M, Bettinger M, Thimme R, Ullrich E, Tanriver Y, Vuong GL, Arnold R, Hemmati P, Wolf D, Ditschkowski M, Jilg C, Wilhelm K, Leiber C, Gerull S, Halter J, Lengerke C, Pabst T, Schroeder T, Kobbe G, Rösler W, Doostkam S, Meckel S, Stabla K, Metzelder SK, Halbach S, Brummer T, Hu Z, Dengjel J, Hackanson B, Schmid C, Holtick U, Scheid C,

- Spyridonidis A, Stölzel F, Ordemann F, Müller LP, Sicre-de-Fontbrune F, Ihorst G, Kuball J, Ehlert JE, Feger D, Wagner EV, Cahn JY, Schnell J, Kuchenbauer F, Bunjes D, Chakraverty R, Richardson S, Gill S, Kröger N, Ayuk F, Vago L, Ciceri F, Müller AM, Kondo T, Teshima T, Klaeger S, Kuster B, Kim D, Weisdorf D, van der Velden W, Dörfel D, Bethge W, Hilgendorf I, Hochhaus A, Andrieux G, Börries M, Busch H, Magenau J, Reddy P, Labopin M, H. Antin J, Henden AS, Hill GR, Kennedy GA, Bar M, Sarma A, McLornan D, Mufti G, Oran B, Rezvani K, Sha O, Negrin RS, Nagler A, Prinz M, Burchert A, Neubauer A, Beelen D, Mackensen A, von Bubnoff N, Herr W, Becher B, Socié G, Caligiuri MA, Ruggiero E, Bonini C, Häcker G, Duyster J, Finke J, Pearce E, Blazar BR, **Zeiser, R.** (2018). Sorafenib promotes graft-versus-leukemia activity in mice and humans through IL-15 production in FLT3-ITD-mutant leukemia cells. *Nature Medicine* 24(3), 282-291; doi:10.1038/nm.4484
9. Prestipino A, Emhardt A, Aumann K, O'Sullivan D, Gorantla SP, Duquesne S, Melchinger W, Braun L, Vuckovic S, Boerries M, Busch H, Halbach S, Pennisi S, Poggio T, Apostolova P, Veratti P, Hettich M, Niedermann G, Bartholomä M, Shoumariyeh K, Jutzi J, Wehrle J, Dierks C, Becker H, Schmitt-Graeff A, Follo M, Pfeifer D, Rohr J, Fuchs S, Ehl S, Hartl FA, Minguet S, Miething C, Heidel F, Kröger N, Trivai I, Brummer T, Finke J, Illert AL, Ruggiero E, Bonini C, Duyster J, Pahl HL, Lane SW, Hill GR, Blazar BR, Bubnoff N, Pearce EL, **Zeiser, R.** (2018). Oncogenic JAK2(V617F) causes PD-L1 expression, mediating immune escape in myeloproliferative neoplasms. *Science Translational Medicine* 10(429); doi:10.1126/scitranslmed.aam7729
10. Schwab L*, Goroncy L*, Palaniyandi S*, Gautam S, Triantafyllopoulou A, Mocsai A, Reichardt W, Karlsson FJ, Radhakrishnan SV, Hanke K, Schmitt-Gräff A, Freudenberg M, von Loewenich FD, Wolf P, Leonhardt F, Baxan N, Pfeifer D, Schmäh O, Schönlé A, Martin SF, Mertelsmann R, Duyster J, JFinke J, Prinz M, Henneke P, Häcker H, Hildebrandt GC*, Häcker G*, **Zeiser, R.*** (2014). Neutrophil granulocytes recruited upon translocation of intestinal bacteria enhance graft-versus-host disease via tissue damage. *Nature Medicine* 20(6), 648-654; doi:10.1038/nm.3517 *equal contribution
11. Wilhelm K, Ganesan J, Müller T, Dürr C, Grimm M, Beilhack A, Kreml CD, Sorichter S, Gerlach UV, Jüttner E, Zerweck A, Gärtner F, Pellegatti P, Di Virgilio F, Ferrari D, Kambham N, Fisch P, Finke J, *Idzko M, **Zeiser, R.*** (2010). Graft-versus-host disease is enhanced by extracellular ATP activating P2X7R. *Nature Medicine* 16(12), 1434-1438; doi:10.1038/nm.2242 *equal contribution

Academic Distinctions - Awards and prizes:

2025	Gottfried Wilhelm Leibniz Prize (DFG)
2024	Mechthild Harf Science Award (DKMS/EBMT)
2023	ERC Advanced grant (EU)
2023	Member of the grants committee of the German Cancer Aid
2022	DGIM Disease prevention Award (DGIM)
2021	CIBSS Award (Cluster of Excellence CIBSS)
2021	Deutscher Krebspreis (German Cancer Award)
2020	Preis der Berlin-Brandenburgischen Akademie der Wissenschaften
2019	Paul Martini Award (Paul Martini Foundation)
2017	Richtzenhain Cancer Research Award (DKFZ)
2016	ERC Consolidator grant (EU)
2015	Jon van Rood Award (European Soc. for Blood & Marrow Transplantation)
2014	Artur Pappenheim Award (Dt. Gesellschaft für Hämatologie/Onkologie)
2013	Heisenberg Professorship (Deutsche Forschungsgemeinschaft)
2011	Theodor Frerichs Award (Deutsche Gesellschaft für Innere Medizin)
2007	BBMT Editorial award for the best publication in 2007 (ASBMT)
2006	Scholar Award (American Society of Hematology)

Data protection and consent to the processing of optional data

If you provide voluntary information (marked as optional) in this CV, your consent is required. Please confirm your consent by checking the box below.

☒ I expressly consent to the processing of the voluntary (optional) information, including “special categories of personal data”¹ in connection with the DFG’s review and decision-making

¹ Special categories of personal data are those “revealing racial or ethnic origin, political opinions, religious or philosophical beliefs, or trade union membership, and (...) genetic data, biometric data for the purpose of uniquely identifying a natural person, data concerning health or data concerning a natural person’s sex life or sexual orientation” (Article 9(1) GDPR).

process regarding my proposal. This also includes forwarding my data to the external reviewers, committee members and, where applicable, foreign partner organisations who are involved in the decision-making process. To the extent that these recipients are located in a third country (outside the European Economic Area), I additionally consent to them being granted access to my data for the above-mentioned purposes, even though a level of data protection comparable to EU law may not be guaranteed. For this reason, compliance with the data protection principles of EU law is not guaranteed in such cases. In this respect, there may be a violation of my fundamental rights and freedoms and resulting damages. This may make it more difficult for me to assert my rights under the General Data Protection Regulation (e.g. information, rectification, erasure, compensation) and, if necessary, to enforce these rights with the help of authorities or in court.

I may **revoke** my consent in whole or in part at any time – with effect for the future, freely and without giving reasons – vis-à-vis the DFG (postmaster@dfg.de). The lawfulness of the processing carried out up to that point remains unaffected. Insofar as I transmit “special categories of personal data” relating to third parties, I confirm that the necessary legitimation under data protection law exists (e.g. based on consent).

I have taken note of the DFG’s Data Protection Notice relating to research funding, which I can access at www.dfg.de/privacy_policy and I will forward it to such persons whose data the DFG processes as a result of being mentioned in this CV.